259 related articles for article (PubMed ID: 27296828)
21. Physical activity in COPD patients decreases short-acting bronchodilator use and the number of exacerbations.
Katajisto M; Koskela J; Lindqvist A; Kilpeläinen M; Laitinen T
Respir Med; 2015 Oct; 109(10):1320-5. PubMed ID: 26298024
[TBL] [Abstract][Full Text] [Related]
22. A phase IIb randomized, chronic-dosing, incomplete block, cross-over study of glycopyrronium, delivered via metered dose inhaler, compared with a placebo and an active control in patients with moderate-to-severe COPD.
Kerwin EM; Spangenthal S; Kollar C; St Rose E; Reisner C
Respir Res; 2018 Mar; 19(1):38. PubMed ID: 29506504
[TBL] [Abstract][Full Text] [Related]
23. Prevalence of overuse of short-acting beta-2 agonists (SABA) and associated factors among patients with asthma in Germany.
Worth H; Criée CP; Vogelmeier CF; Kardos P; Becker EM; Kostev K; Mokros I; Schneider A
Respir Res; 2021 Apr; 22(1):108. PubMed ID: 33863317
[TBL] [Abstract][Full Text] [Related]
24. Mono- and combination therapy of long-acting bronchodilators and inhaled corticosteroids in advanced COPD.
Ohar JA; Donohue JF
Semin Respir Crit Care Med; 2010 Jun; 31(3):321-33. PubMed ID: 20496301
[TBL] [Abstract][Full Text] [Related]
25. Comparative Effectiveness of Long-Acting Beta
Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA
Pharmacotherapy; 2017 Apr; 37(4):447-455. PubMed ID: 28226405
[TBL] [Abstract][Full Text] [Related]
26. Trends and Factors Associated with Nebulized Therapy Prescription in Older Adults with Chronic Obstructive Pulmonary Disease from 2008 to 2015.
Singh M; Duarte AG; Hsu ES; Kuo YF; Sharma G
J Aerosol Med Pulm Drug Deliv; 2020 Jun; 33(3):161-169. PubMed ID: 32017642
[No Abstract] [Full Text] [Related]
27. Treatment patterns for patients hospitalized with chronic obstructive pulmonary disease.
Amin AN; Bollu V; Stensland MD; Netzer L; Ganapathy V
Am J Health Syst Pharm; 2018 Mar; 75(6):359-366. PubMed ID: 29523532
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of ipratropium bromide/salbutamol sulphate administered in a hydrofluoroalkane metered-dose inhaler for the treatment of COPD.
Bhattacharya A; Bhargava S; Singh V; Talwar D; Whig J; Rebello J; Purandare S; Gogtay J
Int J Chron Obstruct Pulmon Dis; 2016; 11():1469-76. PubMed ID: 27418820
[TBL] [Abstract][Full Text] [Related]
29. Bronchodilator reliever use and its association with the economic and humanistic burden of COPD: a propensity-matched study.
Punekar YS; Naya I; Small M; Holbrook T; Wood R; Mullerova H; Valle M
J Med Econ; 2017 Jan; 20(1):28-36. PubMed ID: 27564685
[TBL] [Abstract][Full Text] [Related]
30. Spotlight on glycopyrronium/formoterol fumarate inhalation aerosol in the management of COPD: design, development, and place in therapy.
Dhungana S; Criner GJ
Int J Chron Obstruct Pulmon Dis; 2017; 12():2307-2312. PubMed ID: 28814858
[TBL] [Abstract][Full Text] [Related]
31. Can Assessment of Disease Burden Prior to Changes in Initial COPD Maintenance Treatment Provide Insight into Remaining Unmet Needs? A Retrospective Database Study in UK Primary Care.
Landis SH; Wurst K; Le HV; Bonar K; Punekar YS
COPD; 2017 Feb; 14(1):80-85. PubMed ID: 27819513
[TBL] [Abstract][Full Text] [Related]
32. Use patterns of long-acting bronchodilators in routine COPD care: the OUTPUL study.
Di Martino M; Agabiti N; Bauleo L; Kirchmayer U; Cascini S; Pistelli R; Colamesta V; Patorno E; Pinnarelli L; Fusco D; Perucci CA; Davoli M;
COPD; 2014 Aug; 11(4):414-23. PubMed ID: 24090036
[TBL] [Abstract][Full Text] [Related]
33. Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA® Dry Powder Inhaler.
Prime D; de Backer W; Hamilton M; Cahn A; Preece A; Kelleher D; Baines A; Moore A; Brealey N; Moynihan J
J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):486-97. PubMed ID: 26372467
[TBL] [Abstract][Full Text] [Related]
34. The short, the long and the "ultra-long": why duration of bronchodilator action matters in chronic obstructive pulmonary disease.
Beeh KM; Beier J
Adv Ther; 2010 Mar; 27(3):150-9. PubMed ID: 20411368
[TBL] [Abstract][Full Text] [Related]
35. Higher short-acting beta-agonist use is associated with greater COPD burden.
Gondalia R; Bender BG; Theye B; Stempel DA
Respir Med; 2019; 158():110-113. PubMed ID: 31655317
[TBL] [Abstract][Full Text] [Related]
36. Assessing the clinical value of fast onset and sustained duration of action of long-acting bronchodilators for COPD.
Cazzola M; Beeh KM; Price D; Roche N
Pulm Pharmacol Ther; 2015 Apr; 31():68-78. PubMed ID: 25727846
[TBL] [Abstract][Full Text] [Related]
37. A double-blind crossover study comparing the safety and efficacy of three weeks of Flu/Sal 250/50 bid plus albuterol 180 ug prn q4 hours to Flu/Sal 250/50 bid plus albuterol/Ipratropium bromide 2 puffs prn q4 hours in patients with chronic obstructive pulmonary disease.
Balkissoon R; Make B
COPD; 2008 Aug; 5(4):221-7. PubMed ID: 18671147
[TBL] [Abstract][Full Text] [Related]
38. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Thach C; Patalano F; Banerji D;
Int J Chron Obstruct Pulmon Dis; 2015; 10():1015-26. PubMed ID: 26082625
[TBL] [Abstract][Full Text] [Related]
39. Improvement of pulmonary function and dyspnea by tiotropium in COPD patients using a transdermal beta(2)-agonist.
Akamatsu K; Yamagata T; Takahashi T; Miura K; Maeda S; Yamagata Y; Ichikawa T; Yanagisawa S; Ueshima K; Hirano T; Nakanishi M; Matsunaga K; Minakata Y; Ichinose M
Pulm Pharmacol Ther; 2007; 20(6):701-7. PubMed ID: 17049894
[TBL] [Abstract][Full Text] [Related]
40. Bronchodilators: current and future.
Cazzola M; Matera MG
Clin Chest Med; 2014 Mar; 35(1):191-201. PubMed ID: 24507846
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
